<scp>SWI</scp>/<scp>SNF</scp>‐deficient undifferentiated malignancies: where to draw the line<sup>†</sup>

Cloutier, Basile Tessier; Kleinman, Claudia L.; Foulkes, William D.

doi:10.1002/path.5836

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCCOHT cells also do not show the presence of another SWI/SNF subunit, the SMARCA2 protein, the suppression of which is a consequence of epigenetic gene silencing. In most known cancers with a defective SMARCA4 gene, the correct function of the SMARCA2 protein determines cell survival, so the above phenomenon is a kind of distinction [13,14].…”

Section: Pathogenesismentioning

confidence: 99%

“…A properly functioning SWI/SNF complex has an antagonistic effect on the repressor function of the PRC1 and PRC2 protein complexes in the regulation of gene expression. Loss of function of the SWI/SNF complex leads to increased PRC2 activity with a simultaneous increase in the level of H3K27me3 [3,13,28,14]. Abnormal PRC2 function may promote oncogenesis by repressing tumor suppressor genes, including CDKN2A.…”

Section: Epigenetic Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) - Current State of knowledge

2024

J Oncol Res Ther

View full text Add to dashboard Cite

Small Cell Carcinoma of the Ovary, Hypercalcemic Type -SCCOHT is a rare and extremely malignant gynecological tumor. Both diagnosis and treatment are currently a complex problem in clinical practice, and the prognosis of patients, despite their young age at diagnosis, remains consistently unfavorable. The aim of the study is to present current knowledge about SCCOHT, as well as the results of preclinical studies constituting potentially new therapeutic strategies, based on available literature in the Pub Med database. Promising results have been achieved by research on epigenetic therapies, CDK4/CDK6 inhibitors, immunotherapy, tyrosine kinase inhibitors, as well as the elimination of arginine from the tumor environment. However, individual case reports and the results of preclinical studies available in the PubMed database indicate that in order to improve the long-term results of SCCOHT treatment, combination therapies have to be considered.

show abstract

Section: Pathogenesismentioning

confidence: 99%